216 related articles for article (PubMed ID: 11600103)
1. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions.
Peacock L; Gerlach J
Biol Psychiatry; 2001 Oct; 50(7):501-9. PubMed ID: 11600103
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia.
Lublin H
Clin Neuropharmacol; 1995 Dec; 18(6):533-51. PubMed ID: 8681313
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H; Gerlach J; Mørkeberg F
Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
[TBL] [Abstract][Full Text] [Related]
4. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Peacock L; Hansen L; Mørkeberg F; Gerlach J
Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
[TBL] [Abstract][Full Text] [Related]
5. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Lublin H; Gerlach J; Peacock L
Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
[TBL] [Abstract][Full Text] [Related]
6. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
[TBL] [Abstract][Full Text] [Related]
7. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors.
Andringa G; Drukarch B; Leysen JE; Cools AR; Stoof JC
Eur J Pharmacol; 1999 Jan; 364(1):33-41. PubMed ID: 9920182
[TBL] [Abstract][Full Text] [Related]
8. SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals?
Cools AR; Lubbers L; van Oosten RV; Andringa G
Neuropharmacology; 2002 Feb; 42(2):237-45. PubMed ID: 11804620
[TBL] [Abstract][Full Text] [Related]
9. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
10. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
11. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
[TBL] [Abstract][Full Text] [Related]
12. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
Kistrup K; Gerlach J
Pharmacol Toxicol; 1987 Sep; 61(3):157-61. PubMed ID: 2891133
[TBL] [Abstract][Full Text] [Related]
13. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
[TBL] [Abstract][Full Text] [Related]
14. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
[TBL] [Abstract][Full Text] [Related]
15. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.
Wachtel SR; Brooderson RJ; White FJ
Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670
[TBL] [Abstract][Full Text] [Related]
16. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
Byrnes EM; Bruno JP
Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.
Deveney AM; Waddington JL
Br J Pharmacol; 1995 Oct; 116(3):2120-6. PubMed ID: 8640354
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Lublin H; Gerlach J; Peacock L
Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
[TBL] [Abstract][Full Text] [Related]
19. Effects of dopamine D1-like receptor agonists on food-maintained operant behavior in rats.
Katz JL; Kopajtic TA; Terry P
Behav Pharmacol; 2006 Jun; 17(4):303-9. PubMed ID: 16914948
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
